Synbio International, Inc. (OTC: SYIN) has entered into a strategic licensing, manufacturing, supply, and revenue sharing agreement with MD PHD Wellness, Inc., securing exclusive rights to commercialize MD PHD Wellness’ proprietary nutraceutical formulations throughout the United States and Canada. The agreement covers MD PHD Wellness’ flagship anti-anxiety nutraceutical formulation, which will be marketed under Synbio’s Healing Force™ brand. It also establishes a framework for evaluating and commercializing additional proprietary wellness products over time.
The deal provides Synbio with immediate access to proprietary nutraceutical products without the time and cost burden of developing formulations from scratch, significantly accelerating the company’s path to revenue generation. Under the agreement, MD PHD Wellness will oversee product development, manufacturing, quality assurance, and supply chain management, while Synbio will handle branding, marketing, sales, and distribution. Following recovery of approved manufacturing and commercialization costs, profits from product sales will be shared between the parties.
Claudio Solitario, CEO of Synbio International, called the agreement a "transformational milestone" for the company. "Rather than building a nutraceutical business product by product, we have established a strategic partnership that combines MD PHD’s product development and manufacturing expertise with Synbio’s commercialization capabilities," he said. "It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time."
This partnership positions Synbio to participate in the rapidly expanding global nutraceutical market through a growing portfolio of scientifically developed products, while the company continues to advance its longer-term AI-driven healthcare technologies. The agreement builds on the scientific leadership of MD PHD Wellness, founded by Dr. Robert Lawrence, a physician and scientist with two Ph.D.s in Nuclear Physics and Biomedical Engineering, and co-founded by Dr. David Anderson, an experienced physician and researcher who contributed to developing the licensed formulations.
Synbio’s broader strategy is to build a diversified healthcare company that pairs near-term revenue from commercial wellness products with longer-term value creation from its AI-driven mental health technologies. This dual-track approach provides multiple avenues for growth while establishing recurring commercial revenue that can support continued investment in innovation. Synbio International is a company focused on clinically validating an AI-driven software that screens for mental health conditions using facial analysis. To generate early revenue while its software advances through validation, Synbio plans to launch a line of nutraceutical products sold directly to consumers online in 2026.
For more information, visit Synbio International's website.
